Atyr Pharma, Inc. · NASDAQ:ATYR
Atyr Pharma — Investor Presentation (January 2021)
32 slides from Atyr Pharma's investor presentation, Jan 11, 2021
Slide 1: A New Path to Medicine
A New Path to Medicine January 2021 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “should,” “expect,”
Slide 3: aTyr: A New Path to Medicine
aTyr: A New Path to Medicine Mission Develop a new class of medicines based on proprietary biology platform Phase 2 clinical program: ATYR1923 Potential first-in-class immunomodulator for severe inflammatory lung diseases Phase 1b/2a study in pulmonary sarcoidosis—target enrollment complete and data
Slide 4: aTyr Development Pipeline
aTyr Development Pipeline 4 CTD-ILD: connective tissue disease-related ILD (e.g. Scleroderma-related ILD); CHP: chronic hypersensitivity pneumonitis In partnership with Kyorin Pharmaceutical Co., Ltd. Includes research collaboration with CSL Behring, Ltd.
Slide 5: tRNA Synthetases May Have Novel Functions Extracellularly
tRNA Synthetases May Have Novel Functions Extracellularly 5
Slide 6: ATYR1923 A Novel Immunomodulator for Inflammatory Lung Disease
ATYR1923 A Novel Immunomodulator for Inflammatory Lung Disease
Slide 7: A Novel Mechanism to Treat Inflammation
A Novel Mechanism to Treat Inflammation 7 Representative histology showing immune cell infiltrate in a rat model of bleomycin induced lung fibrosis presented at the American Thoracic Society annual meeting 2018. Injured lung ATYR1923 treated Healthy lung
Slide 8: ATYR1923: Early Data Supports Therapeutic Potential in Immune-Mediated Lung Disease
ATYR1923: Early Data Supports Therapeutic Potential in Immune-Mediated Lung Disease Fc fusion protein, based on lung-enriched histidyl-tRNA synthetase (HARS) fragment, recombinantly expressed in E. coli Receptor screen identified selective binding to NRP2, a cell surface receptor upregulated on key
Slide 9: Demonstrated Effect in Animal Lung Injury Models
Demonstrated Effect in Animal Lung Injury Models 9 Data available at https://www.atyrpharma.com/our-science/publications/ Fibrosis Inflammation Bleomycin-Induced Lung Fibrosis (IPF) P. acnes (Sarcoidosis) Sclerodermatous GvHD (SSc-ILD) SKG mice (RA-ILD) S. Rectivirgula (CHP) ↓ inflammation / fibrosi
Slide 10: ATYR1923 Mechanism of Action in Inflammatory Lung Disease
ATYR1923 Mechanism of Action in Inflammatory Lung Disease 10
Slide 11: ATYR1923 Interstitial Lung Disease
ATYR1923 Interstitial Lung Disease
Slide 12: ILDs Share Common Immune Pathology Leading to Fibrosis
ILDs Share Common Immune Pathology Leading to Fibrosis 12 Slide adapted from Dr. Steven Nathan, Medical Director, Advanced Lung Disease and Transplant Program at Inova Fairfax Hospital, Falls Church, VA Fibrosis Pulmonary Sarcoidosis Connective Tissue Disease related – ILD (CTD-ILD) Chronic Hypersen
Slide 13: Market Opportunity in Inflammatory Interstitial Lung Disease
Market Opportunity in Inflammatory Interstitial Lung Disease 13 Lederer, Martinez. NEJM 2018 All ILDs individually have potential for orphan status aTyr estimates for ATYR1923 in Pulmonary Sarcoidosis, CHP, CTD-ILD; excludes IPF >200 types of ILD: 4 major types comprise 80% of patients Limited stand
Slide 14: First ATYR1923 Indication: Pulmonary Sarcoidosis
First ATYR1923 Indication: Pulmonary Sarcoidosis Inflammatory disease of unknown etiology characterized by the formation of granulomas (clumps of immune cells) T cell driven: CD4+ (Th1 / Th17) Pulmonary sarcoidosis occurs in ~90% of all sarcoidosis patients Treatment options are limited with associa
Slide 15: Phase 1b/2a Study in Pulmonary Sarcoidosis Ongoing
Phase 1b/2a Study in Pulmonary Sarcoidosis Ongoing 15 Target enrollment completed Data expected Q3 2021
Slide 16: Phase 1b/2a Pulmonary Sarcoidosis Study Schema
Phase 1b/2a Pulmonary Sarcoidosis Study Schema 16 (1) subtherapeutic dose 0 4 8 12 16 20 24 24-week Study Period Week Each Cohort: Dose Escalation Review after 6 patients have received ≥3 doses of study drug ATYR1923 Placebo 5 mg OCS(1) Steroid taper every 2 weeks Primary endpoint If stable on 5 mg,
Slide 17: ATYR1923 Japan Collaboration Kyorin
ATYR1923 Japan Collaboration Kyorin Overview Founded: 1923 Focus: Respiratory, ENT, Urology 1600 employees: incl. 350 in R&D; 750 sales reps covering top respiratory centers in Japan Sales: ~$1b USD Market cap: $1.2b USD (4569:JP TSE) Key Terms Scope: ATYR1923; Japan; ILD Upfront payment: $8m Develo
Slide 18: ATYR1923 COVID-19 Related Severe Respiratory Complications
ATYR1923 COVID-19 Related Severe Respiratory Complications
Slide 19: Phase 2 Study in COVID-19 Related Severe Respiratory Complications
Phase 2 Study in COVID-19 Related Severe Respiratory Complications 19 Topline data reported January 2021 Full data set, including biomarker analysis, expected Q1 2021
Slide 20: Highlights of Topline Results for Safety and Key Recovery Metrics
Highlights of Topline Results for Safety and Key Recovery Metrics Study Met Primary Safety Endpoint in Moderate to Severe Hospitalized Patients ATYR1923 was generally safe and well-tolerated in both the 1.0 and 3.0 mg/kg treatment groups Adverse events were mostly mild or moderate in severity and th
Slide 21: Key Insights from Preliminary Demographics and Baseline Characteristics
Key Insights from Preliminary Demographics and Baseline Characteristics Demographics and baseline disease characteristics were largely balanced except for some key risk factors which were disproportionately randomized to ATYR1923 groups: More patients over the age of 65 More patients with severe hyp
Slide 22: NRP2 Antibodies Regulating Diverse Disease Pathways
NRP2 Antibodies Regulating Diverse Disease Pathways
Slide 23: NRP2: A Novel Therapeutic Target
NRP2: A Novel Therapeutic Target NRP2 is a potentially novel drug target for cancer and inflammatory disorders Acts as a co-receptor for VEGF, semaphorins and certain chemokines (e.g., CCL19) Highly expressed on certain tumors and upregulated on immune cells during inflammation Tumor expression is a
Slide 24: aTyr is Developing Humanized NRP2 Antibodies Targeting Diverse Pathways
aTyr is Developing Humanized NRP2 Antibodies Targeting Diverse Pathways 24 (1) Distinct from ATYR1923 interaction with NRP2 SEMA3F VEGF Dimerization domain a1 a2 b1 b2 c ATYR2810 CCR7 Ligand Blockers a-NRP2-14 aTyr lead antibodies(1)
Slide 25: ATYR2810: Lead Anti-Neuropilin-2 Antibody IND Candidate for Cancer
ATYR2810: Lead Anti-Neuropilin-2 Antibody IND Candidate for Cancer ATYR2810 is a humanized monoclonal antibody that specifically and functionally blocks the interaction between NRP2 and VEGF The role of NRP2 and VEGF signaling in the tumor microenvironment and its importance in the progression of ce
Slide 26: Early Pre-clinical Data Support Development in Oncology
Early Pre-clinical Data Support Development in Oncology 26 AACR Virtual Meeting II – June 22-24, 2020; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0..0001 Increases Sensitivity to Chemotherapy in Triple-Negative Breast Cancer Model Blocks VEGF binding to NRP2
Slide 27: tRNA Synthetases A Potential New Therapeutic Protein Class
tRNA Synthetases A Potential New Therapeutic Protein Class
Slide 28: tRNA Synthetases: A Potential New Therapeutic Protein Class
tRNA Synthetases: A Potential New Therapeutic Protein Class aTyr owns IP covering proteins derived from all 20 tRNA synthetase gene families Lead program ATYR1923 is based on a naturally occurring splice variant of one of these families, histidyl-tRNA synthetase (HARS) tRNA synthetases are secreted
Slide 29: A New Path to Medicine
allyr A New Path to Medicine
Slide 30: aTyr: A New Path to Medicine
aTyr: A New Path to Medicine Platform of proprietary new biology Phase 2 clinical program: ATYR1923 Novel MOA for inflammatory lung disease Demonstrated effect in multiple animal lung injury models Phase 1b/2a clinical study in pulmonary sarcoidosis completed enrollment in US – positive interim safe
Slide 31: Upcoming Catalysts
Upcoming Catalysts Phase 1b/2a results in pulmonary sarcoidosis patients expected Q3 2021 ATYR1923 Kyorin’s Phase 1 in healthy volunteers to support trials for ILD in Japan initiated in Q3 2020 Phase 2 full data set in COVID-19 patients expected Q1 2021 ATYR2810 IND enabling activities for the first
Slide 32: Thank You
Thank You